Synthace collaborates with MSD to develop biomanufacturing platform

Published: 28-Oct-2015
Research & Development Pharmaceutical

Will use Synthace's high throughput methods and tools for a number of undisclosed molecules


Synthace, a London, UK-based synthetic biology company has entered into a new relationship with MSD (known as Merck & Co in the US and Canada).

The collaboration will use Synthace’s high throughput methods and tools to develop a biomanufacturing platform for a number of undisclosed molecules. The tie-up builds on a previous agreement with MSD initiated in 2014.

'We are delighted to extend our relationship with MSD, a recognised leader in bioprocess innovation within the pharma industry,' said Tim Fell, Chief Executive of Synthace.

'This collaboration is focused on the rapid development of a high productivity, low cost of goods biomanufacturing process through the use of our next-generation approach to simultaneous genetic and process optimisation.'

  • Companies:
  • Merck MSD
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Read more
Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  2. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  3. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  5. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Regulatory

Merck's sacituzumab tirumotecan granted Breakthrough Therapy Designation by the FDA

The antibody-drug conjugate (ADC) can be used to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Research & Development

Merck acquires $700m clinical-stage bispecific antibody from Curon Biopharmaceutical

The CD3xCD19-targeting T-cell engager is currently being evaluated in Phase I/Ib/II clinical trials for a range of B-cell malignancies
Manufacturing

Merck and Daiichi Sankyo expand antibody drug conjugate commercialisation agreement

The companies will collaborate to commercialise MK-6070, a T-cell engager which has shown promise in treating patients with small cell lung cancer (SCLC)
Research & Development

Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants

A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Subscribe now